bristol myers squibb biontech - Search News

News

BioNTech, Bristol Myers Squibb and cancer immunotherapy

Reuters on MSN · 4d

Bristol Myers agrees up to $11.1 billion deal with BioNTech to shake up cancer immunotherapy

Bristol Myers Squibb has agreed to pay up to $11.1 billion to partner with Germany's BioNTech and develop the latter's next-generation cancer immunotherapy, which could take on rival Merck & Co's best-selling drug Keytruda.

Seeking Alpha · 1d

Bristol-Myers And BioNTech Deal: Good For Both Parties, But One Is The Better Investment

Bristol-Myers Squibb and BioNTech announced a major deal worth up to $11 billion in early June. Click here to find out why I like BMY more than BNTX.

Bristol Myers Squibb, BioNTech partner on $11B cancer drug deal

Bristol Myers Squibb and BioNTech to co-develop cancer immunotherapy BNT327 in a deal worth up to $11.1 billion.

Medical Dialogues1d

Bristol Myers Squibb, BioNTech ink pact to co-develop, co-commercialize investigational bispecific antibody for multiple solid tumor types

Princeton: BioNTech SE and Bristol Myers Squibb have announced that the companies have entered into an agreement for the ...

4d

BioNTech-Aktie steigt - Bristol zahlt bis zu $11,1 Mrd. in Krebsmedikament-Deal

Bristol-Myers Squibb wird BioNTech bis zu 11,1 Milliarden Dollar (9,7 Milliarden Euro) für die Lizenzierung eines ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results